Peter J. Boerrigter

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 416 citations

Urological Research, Urology, Voiding Dysfunction +6

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization

Nicole G.M. Beckers, Nicholas S. Macklon, Paul Devroey et al. · Fertility and Sterility · 2003 · 63 citations

Infertility, Developmental Biology, Fertility +13

774 DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

Christopher R. Chapple, J J Wyndaele, P. Van Kerrebroeck et al. · European Urology Supplements · 2010 · 46 citations

Molecular Pharmacology, Urological Research, Urology +4

886 THE EFFICACY AND TOLERABILITY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER – RESULTS FROM A EUROPEAN–AUSTRALIAN PHASE III TRIAL

V. Khullar, J. Cambronero, Peter Ströberg et al. · European Urology Supplements · 2011 · 37 citations

Urological Research, Urology, Voiding Dysfunction +4

Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix

Peter J. Boerrigter · Human Reproduction · 2002 · 30 citations · Full text